{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06507306",
            "orgStudyIdInfo": {
                "id": "KQB198-101"
            },
            "organization": {
                "fullName": "Kumquat Biosciences Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies",
            "officialTitle": "A Phase 1/1b, Open-label, Multicenter, Dose Escalation and Dose Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB198 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-study-to-investigate-the-safety-and-efficacy-of-as-monotherapy-and-in-combination-in-participants-with-advanced-solid-malignancies"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-06-03",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-07-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-01-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-07-01",
            "studyFirstSubmitQcDate": "2024-07-11",
            "studyFirstPostDateStruct": {
                "date": "2024-07-18",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-11",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-18",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Kumquat Biosciences Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The goal of this clinical trial is to learn if KQB198 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB198. The main questions it aims to answer are:\n\n* What is the safe dose of KQB198 by itself or in combination with other anti-cancer drugs?\n* Does KQB198 alone or in combination with other anti-cancer drugs decrease the size of the tumor?\n* What happens to KQB198 in the body?\n\nParticipants will:\n\n* Take KQB198 daily, alone or in combination with another anti-cancer drug\n* Visit the clinic about 8 times in the first 8 weeks, and then once every 4 weeks after that"
        },
        "conditionsModule": {
            "conditions": [
                "Solid Tumor, Adult"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 100,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Monotherapy Dose Escalation",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: KQB198"
                    ]
                },
                {
                    "label": "Combo Therapy Dose Escalation",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: KQB198",
                        "Drug: osimertinib"
                    ]
                },
                {
                    "label": "Combo Therapy Dose Expansion - RP2D",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: KQB198",
                        "Drug: osimertinib"
                    ]
                },
                {
                    "label": "Combo Therapy Dose Expansion - RP2D-1",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: KQB198",
                        "Drug: osimertinib"
                    ]
                },
                {
                    "label": "Combo Therapy Dose Expansion OBD",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: KQB198",
                        "Drug: osimertinib"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "KQB198",
                    "description": "Oral KQB198",
                    "armGroupLabels": [
                        "Combo Therapy Dose Escalation",
                        "Combo Therapy Dose Expansion - RP2D",
                        "Combo Therapy Dose Expansion - RP2D-1",
                        "Combo Therapy Dose Expansion OBD",
                        "Monotherapy Dose Escalation"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "osimertinib",
                    "description": "Oral osimertinib",
                    "armGroupLabels": [
                        "Combo Therapy Dose Escalation",
                        "Combo Therapy Dose Expansion - RP2D",
                        "Combo Therapy Dose Expansion - RP2D-1",
                        "Combo Therapy Dose Expansion OBD"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of patients who experience treatment-emergent adverse events, serious adverse events, and dose-limiting toxicities (Part 1)",
                    "description": "Safety characterized by type, incidence, severity, timing, seriousness and relationship to study treatment of AEs, SAEs, and DLTs, from first dose of study treatment to 28 days after last dose of study treatment.",
                    "timeFrame": "28 Days"
                },
                {
                    "measure": "Recommended Phase 2 Dose (RP2D) (Part 1)",
                    "description": "Evaluate safety and assess number of patients with dose-limiting toxicity to determine the RP2D.",
                    "timeFrame": "up to 30 months"
                },
                {
                    "measure": "Efficacy and Optimal Biologic Dose of study treatment, as measured by Objective Response Rate (ORR) (Parts 2 and 3)",
                    "description": "Objective response is the proportion of subjects that experience confirmed complete response (CR) or partial response (PR) based on RECIST v1.1 during the time period from 1st dose of study treatment until last dose.",
                    "timeFrame": "up to 30 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Concentration-time curve (AUC)",
                    "timeFrame": "up to 30 months"
                },
                {
                    "measure": "Maximum plasma concentration (Cmax)",
                    "timeFrame": "up to 30 months"
                },
                {
                    "measure": "Time to maximum plasma concentration (tmax)",
                    "timeFrame": "up to 30 months"
                },
                {
                    "measure": "Overall survival (OS)",
                    "timeFrame": "up to 30 months"
                },
                {
                    "measure": "Progression-free survival (PFS)",
                    "timeFrame": "up to 30 months"
                },
                {
                    "measure": "Overall response rate (ORR)",
                    "timeFrame": "up to 30 months"
                },
                {
                    "measure": "Duration of response (DOR)",
                    "timeFrame": "up to 30 months"
                },
                {
                    "measure": "Time to response (TTR)",
                    "timeFrame": "up to 30 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* PART 1: Histologically confirmed diagnosis of a solid tumor malignancy with any of the following oncogenic mutations: EGFR, RAS, PTPN11, or SOS1 mutations, or inactivating mutations of NF1.\n* PART 1 (Osimertinib arm) and Part 2 Cohort A: Histologically confirmed diagnosis of NSCLC with activating EGFR mutation and progression on osimertinib\n* Part 3 Cohort A: Histologically confirmed diagnosis of NSCLC with exon 20 insertion EGFR mutation\n* Unresectable or metastatic disease\n* No available treatment with curative intent\n* Adequate organ function\n* Measurable disease per RECIST 1.1.\n\nExclusion Criteria:\n\n* Prior therapy with a similar mechanism of action to KQB198\n* History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions likely to alter absorption of study treatment or result in inability to swallow\n* History of interstitial lung disease\n* Cardiac abnormalities",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Kumquat Clinical Development",
                    "role": "CONTACT",
                    "phone": "(858) 214-2700",
                    "email": "kumquatstudies@kumquatbio.com"
                }
            ],
            "locations": [
                {
                    "facility": "The Lindner Center for Research and Education at The Christ Hospital",
                    "status": "RECRUITING",
                    "city": "Cincinnati",
                    "state": "Ohio",
                    "zip": "45219",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Abby Reed",
                            "role": "CONTACT",
                            "email": "abby.reed@thechristhospital.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.12713,
                        "lon": -84.51435
                    }
                },
                {
                    "facility": "NEXT Oncology",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78229",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Jordan Georg",
                            "role": "CONTACT",
                            "email": "jgeorg@nextoncology.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                },
                {
                    "facility": "NEXT Oncology",
                    "status": "RECRUITING",
                    "city": "Fairfax",
                    "state": "Virginia",
                    "zip": "22031",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Blake Patterson",
                            "role": "CONTACT",
                            "email": "bpatterson@nextoncology.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.84622,
                        "lon": -77.30637
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000596361",
                    "term": "Osimertinib"
                }
            ],
            "ancestors": [
                {
                    "id": "D000092004",
                    "term": "Tyrosine Kinase Inhibitors"
                },
                {
                    "id": "D000047428",
                    "term": "Protein Kinase Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M145673",
                    "name": "Osimertinib",
                    "asFound": "Methylprednisolone",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2889",
                    "name": "Tyrosine Kinase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M25820",
                    "name": "Protein Kinase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "T22",
                    "name": "Tyrosine",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "AA",
                    "name": "Amino Acids"
                }
            ]
        }
    },
    "hasResults": false
}